Nebulcort (Flunisolide)

Flunisolide binds to glucocorticoid receptors inside cells, forming a complex that moves to the nucleus and alters gene transcription. This action suppresses the production of inflammatory cytokines, chemokines, and other mediators, leading to decreased airway inflammation and reduced swelling of the respiratory mucosa.

The dosage of Nebulcort is individualized and determined by the prescribing healthcare professional based on the patient’s age, disease severity, and response to therapy. Patients should follow the prescriber’s instructions and the product’s label; no standard dosing regimen is provided here.

Safety data for flunisolide during pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss them with the patient. If treatment is considered necessary, it should be used only under medical supervision.

To place an order, submit an enquiry on the Nebulcort product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nebulcort delivers flunisolide, a medium‑potency inhaled corticosteroid. Compared with higher‑potency agents such as budesonide or fluticasone, flunisolide may require slightly higher doses to achieve similar anti‑inflammatory effects, but it is often well tolerated and suitable for patients who need moderate control of airway inflammation.

Nebulcort should be stored at room temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the device clean according to the manufacturer’s instructions and avoid exposing the inhaler to extreme temperatures or humidity, which could affect drug potency.

Nebulcort is administered by inhalation using a metered‑dose inhaler or a nebulizer, as directed by the prescriber. Patients should shake the device (if required), exhale fully, then inhale the dose slowly and hold their breath for a few seconds to maximize pulmonary deposition.

Serious risks include adrenal suppression, which can lead to reduced endogenous cortisol production, especially with high‑dose or prolonged use, and growth retardation in children. Rarely, severe allergic reactions such as anaphylaxis may occur. Patients should be monitored for these events and advised to seek immediate medical care if symptoms arise.

Nebulcort is contraindicated in individuals with a known hypersensitivity to flunisolide or any component of the inhaler formulation. It should also be avoided in patients with untreated systemic fungal infections or those who have experienced severe adverse reactions to other inhaled corticosteroids.